All Cosmos Bio-Tech Holding Corp. (4148) AI Stock Analysis

All Cosmos Bio-Tech Holding Corp.

(TWSE:4148)

Select Model

Rating:61Neutral

Price Target:TWD 30.00▲(2.04% Upside)

Action:initiatedcoverage

Date:11/09/26

Mixed financial stability from solid balance sheet is offset by weak technical momentum; attractive valuation provides partial support.

Positive Factors

Conservative balance sheetLow leverage and expanding equity provide financial resilience while the company scales its asset base. A debt-to-equity ratio of about 0.14 limits financing pressure, preserves borrowing capacity, and gives management greater flexibility to fund operations or growth through changing conditions.

Negative Factors

Profitability below prior peaksCurrent profitability remains materially below the company’s prior-cycle highs, limiting the earnings produced from each unit of revenue and invested capital. Unless margins and returns recover, the business may have less capacity to compound equity value or absorb operational setbacks.

All Cosmos Bio-Tech Holding Corp. (4148) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 1.99B
Dividend Yield: 3.40%
Average Volume (3M): 46.20K
Price to Earnings (P/E): 10.7
Beta (1Y): 0.14
Revenue Growth: 15.66%
EPS Growth: 31.51%
Country: TW
Employees: 368
Sector: General
Sector Strength: 55
Industry: Agricultural Inputs

All Cosmos Bio-Tech Holding Corp. Business Overview & Revenue Model

Company Description

All Cosmos Bio-Tech Holding Corporation, through its various operating units, primarily focuses on the production and distribution of bio-organic and bio-chemical compound fertilizers across Malaysia. The company also dedicates efforts to the researc...

All Cosmos Bio-Tech Holding Corp. Financial Statement Overview

Summary

Mixed profile: strong balance sheet with low leverage (score 81) offset by volatile cash flows (47) and fluctuating revenues with thin margins (62).

Income Statement

62Positive

Balance Sheet

81Very Positive

Cash Flow

47Neutral

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	3.17B	2.95B	2.46B	2.83B	3.70B	2.20B
Gross Profit	897.64M	829.47M	668.59M	587.98M	1.14B	594.37M
EBITDA	394.27M	362.56M	312.83M	310.76M	699.84M	373.03M
Net Income	185.78M	153.00M	128.59M	139.36M	368.20M	198.13M
Balance Sheet
Total Assets	4.55B	4.22B	3.67B	3.67B	4.11B	2.97B
Cash, Cash Equivalents and Short-Term Investments	1.42B	1.44B	1.25B	1.66B	1.47B	930.13M
Total Debt	612.75M	381.29M	261.61M	543.09M	942.46M	311.31M
Total Liabilities	1.04B	779.83M	540.27M	859.54M	1.25B	591.28M
Stockholders Equity	2.77B	2.74B	2.52B	2.25B	2.37B	1.99B
Cash Flow
Free Cash Flow	186.53M	209.08M	-88.06M	795.82M	-17.02M	-171.49M
Operating Cash Flow	219.52M	251.93M	54.19M	959.24M	43.84M	-67.64M
Investing Cash Flow	-294.23M	-277.80M	-228.46M	-202.98M	-4.67M	-108.17M
Financing Cash Flow	58.61M	82.94M	-428.49M	-549.88M	490.39M	196.10M

All Cosmos Bio-Tech Holding Corp. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:4148 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TW:4911	72Outperform	TWD 1.74B	18.66	―	4.66%	-26.73%	-34.96%
TW:6986	67Neutral	TWD 1.96B	15.55	―	0.52%	―	―
TW:4148	61Neutral	TWD 1.96B	10.66	―	3.40%	15.66%	31.51%
TW:1295	59Neutral	TWD 1.58B	10.17	―	7.14%	-5.28%	-27.33%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%

* General Sector Average

Performance Comparison

TW:4148 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:4148	All Cosmos Bio-Tech Holding Corp.	29.40	-11.51	-28.13%
TW:1295	Synbio Tech Inc	41.90	-49.75	-54.28%
TW:4911	G&E Herbal Biotechnology Co., Ltd.	25.00	-18.42	-42.42%
TW:6808	3D Global Biotech Inc.	26.10	-18.35	-41.29%
TW:6986	HeXun Biosciences Co Ltd	37.50	-21.83	-36.79%
TW:7507	Enrestec, Inc.	17.60	-23.40	-57.07%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

All Cosmos Bio-Tech Holding Corp. AI Stock Analysis